XML 63 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]    
Cash and cash equivalents $ 433,508,000 $ 678,393,000
Other-than-temporary impairment loss $ 0  
Percentage of pre-launch inventory capitalized of aggregate inventory balance 37.00% 29.00%
Net unbilled co-development revenue $ 4,030,000 $ 0
Profit share liability 10,725,000 6,547,000
Astellas Agreement [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Unbilled contract assets, change in estimated variable consideration 4,000,000.0  
AstraZeneca Agreements [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Net unbilled co-development revenue 3,700,000  
AstraZeneca Agreements [Member] | China [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Profit share liability $ 7,000,000.0 7,000,000.0
Maximum [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Contractual maturities of available-for-sale investments 4 years  
Foreign subsidiaries [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Cash and cash equivalents $ 76,500,000 $ 66,000,000.0